These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 23222541)

  • 1. High-resolution crystal structure of human protease-activated receptor 1.
    Zhang C; Srinivasan Y; Arlow DH; Fung JJ; Palmer D; Zheng Y; Green HF; Pandey A; Dror RO; Shaw DE; Weis WI; Coughlin SR; Kobilka BK
    Nature; 2012 Dec; 492(7429):387-92. PubMed ID: 23222541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule.
    Bokoch MP; Jo H; Valcourt JR; Srinivasan Y; Pan AC; Capponi S; Grabe M; Dror RO; Shaw DE; DeGrado WF; Coughlin SR
    Biochemistry; 2018 Oct; 57(39):5748-5758. PubMed ID: 30102523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating detailed interactions between novel PAR1 antagonist F16357 and the receptor using docking and molecular dynamic simulations.
    Readmond C; Wu C
    J Mol Graph Model; 2017 Oct; 77():205-217. PubMed ID: 28881236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist.
    Spoerri PM; Kato HE; Pfreundschuh M; Mari SA; Serdiuk T; Thoma J; Sapra KT; Zhang C; Kobilka BK; Müller DJ
    Structure; 2018 Jun; 26(6):829-838.e4. PubMed ID: 29731231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulated shedding of PAR1 N-terminal exodomain from endothelial cells.
    Ludeman MJ; Zheng YW; Ishii K; Coughlin SR
    J Biol Chem; 2004 Apr; 279(18):18592-9. PubMed ID: 14982936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
    Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
    Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects.
    Schuepbach RA; Madon J; Ender M; Galli P; Riewald M
    J Thromb Haemost; 2012 Aug; 10(8):1675-84. PubMed ID: 22712885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
    Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
    Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics.
    van den Eshof BL; Hoogendijk AJ; Simpson PJ; van Alphen FPJ; Zanivan S; Mertens K; Meijer AB; van den Biggelaar M
    Arterioscler Thromb Vasc Biol; 2017 Oct; 37(10):1891-1902. PubMed ID: 28818855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1.
    Gandhi PS; Chen Z; Di Cera E
    J Biol Chem; 2010 May; 285(20):15393-15398. PubMed ID: 20236938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PAR1's tethered ligand.
    Hammes SR; Coughlin SR
    Biochemistry; 1999 Feb; 38(8):2486-93. PubMed ID: 10029543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.
    Gandhi DM; Majewski MW; Rosas R; Kentala K; Foster TJ; Greve E; Dockendorff C
    Bioorg Med Chem; 2018 May; 26(9):2514-2529. PubMed ID: 29685684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PAR1: Now What?
    Flaumenhaft R; De Ceunynck K
    Trends Pharmacol Sci; 2017 Aug; 38(8):701-716. PubMed ID: 28558960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insight into allosteric modulation of protease-activated receptor 2.
    Cheng RKY; Fiez-Vandal C; Schlenker O; Edman K; Aggeler B; Brown DG; Brown GA; Cooke RM; Dumelin CE; Doré AS; Geschwindner S; Grebner C; Hermansson NO; Jazayeri A; Johansson P; Leong L; Prihandoko R; Rappas M; Soutter H; Snijder A; Sundström L; Tehan B; Thornton P; Troast D; Wiggin G; Zhukov A; Marshall FH; Dekker N
    Nature; 2017 May; 545(7652):112-115. PubMed ID: 28445455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry.
    Loew D; Perrault C; Morales M; Moog S; Ravanat C; Schuhler S; Arcone R; Pietropaolo C; Cazenave JP; van Dorsselaer A; Lanza F
    Biochemistry; 2000 Sep; 39(35):10812-22. PubMed ID: 10978167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar.
    Aisiku O; Peters CG; De Ceunynck K; Ghosh CC; Dilks JR; Fustolo-Gunnink SF; Huang M; Dockendorff C; Parikh SM; Flaumenhaft R
    Blood; 2015 Mar; 125(12):1976-85. PubMed ID: 25587041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications.
    Gutiérrez-Rodríguez M; Herranz R
    Curr Top Med Chem; 2015; 15(20):2080-114. PubMed ID: 25986685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational Plasticity of Human Protease-Activated Receptor 1 upon Antagonist- and Agonist-Binding.
    Spoerri PM; Sapra KT; Zhang C; Mari SA; Kato HE; Kobilka BK; Müller DJ
    Structure; 2019 Oct; 27(10):1517-1526.e3. PubMed ID: 31422910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How the protease thrombin talks to cells.
    Coughlin SR
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11023-7. PubMed ID: 10500117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.
    Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE
    Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.